SAN DIEGO, April 4, 2011 /PRNewswire/ -- Antibiotics are among the most important advances in human health, but their use and misuse over the past 70 years have increased the number and types of microorganisms resistant to antibiotics – resulting in deaths, greater suffering and disability, and higher healthcare costs. For World Health Day 2011, the World Health Organization will call on governments and stakeholders to implement the policies and practices needed to prevent and counter the emergence of highly resistant microorganisms. The challenge posed to the pharmaceutical and biotechnology industries is loud and clear – only seven new antibiotics have been introduced since 2003. A press conference on April 7 will feature innovators in antibiotic research and development from industry and academia that are making strides to combat this problem.
Press Conference: Innovation in Antibiotics; Medicine for the Next Wave of Bacterial Infections
Jeffrey Stein, Ph.D., President and CEO, Trius Therapeutics 
Trius is focusing on the development of innovative antibiotics for life-threatening infections. Trius is in the final stage of clinical development for torezolid phosphate, a next generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).Trius has worked closely with FDA to define a path to market approval for antibiotics that are fast acting and with low acquisition of microbial resistance.
Daniel Burgess, President and CEO, Mpex Pharmaceuticals 
Mpex is in the final stage of clinical testing of a proprietary inhalable formulation of levofloxacin for the treatment of microbial infections in patients with cystic fibrosis. The company's mission is t